Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Katelyn Willis is the Cell Biology Group Leader at Inhibrx. Prior to joining Inhibrx in 2014, Dr. Willis was a postdoctoral scholar at the Moores Cancer Center at UCSD, where she completed the Cancer Therapeutics Training (CT2) and Clinical Research Enhancement through Supplemental Training (CREST) programs. Her research focused on small molecule drug combinations for the treatment of ovarian cancer. Dr. Willis received her B.A. in Biology from Amherst College and her Ph.D. in Molecular and Medical Pharmacology from UCLA, where she designed and engineered antibodies for diagnostic and therapeutic applications.